In addition, although more and more studies have shown that elevated levels of Lp-PLA2 is a high-risk underlying factor for cardiovascular diseases, an authoritative randomized controlled clinical trial study shows that in patients with stable coronary heart disease, the Lp-PLA2 inhibitor darapladib did not significantly reduce the probability of cardiovascular death, myocardial infarction or stroke in such patients (White et al., 2014). The gene discussed is PLA2G7; the disease is myocardial infarction.